SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eikon Therapeutics Presents Updated EIK1001 Data at ESMO Congress

The company presented updated data from the TeLuRide-005 study of EIK1001 with pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer.

EIKN

Related stories